Abbvie (ABBV) P/E (2013 - 2026)
Abbvie (ABBV) P/E from Apr 1, 2013 to Jul 21, 2026. The TTM Abbvie (ABBV) P/E is 145.91. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Abbvie (ABBV)
| Year | P/E | Change |
|---|---|---|
| 2026 | 145.91 | +43.39% |
| 2025 | 101.76 | +96.83% |
| 2024 | 51.70 | +50.66% |
| 2023 | 34.31 | +50.39% |
| 2022 | 22.82 | -6.61% |
| 2021 | 24.43 | -5.12% |
| 2020 | 25.75 | +52.69% |
| 2019 | 16.86 | +7.07% |
| 2018 | 15.75 | -30.42% |
| 2017 | 22.64 | +28.63% |
| 2016 | 17.60 | -24.21% |
| 2015 | 23.22 | -20.99% |
| 2014 | 29.39 | +5.06% |
| 2013 | 27.97 | N/A |
Comparison Abbvie (ABBV) P/E with competitors
Abbvie (ABBV) P/E is 145.91.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -93.07% |
| PFE | Pfizer Inc | 11.65 | -92.01% |
| NVO | Novo Nordisk | 11.79 | -91.92% |
| GSK | GSK Plc | 12.10 | -91.70% |
| SNY | Sanofi | 12.12 | -91.69% |
| BMY | Bristol-Myers Squibb Company | 13.82 | -90.53% |
| OGN | Organon & Company | 14.33 | -90.18% |
| BIIB | Biogen Inc | 17.41 | -88.07% |
| GILD | Gilead Sciences Inc | 17.75 | -87.84% |
| NVS | Novartis AG | 21.60 | -85.20% |
| JNJ | Johnson & Johnson | 22.09 | -84.86% |
| AMGN | AMGEN Inc | 24.75 | -83.04% |
| MRK | Merck & Co Inc | 26.93 | -81.55% |
| AZN | Astrazeneca plc | 28.44 | -80.51% |
| LLY | Lilly(Eli) & Company | 48.44 | -66.80% |